Prostate cancer is one of the most frequent malignant tumors at men. The androgen-deprivation therapy is the part of cancer treatment. It could be used both in the early stage of prostate cancer and in the bone metastases. From this reason the antiandrogen drugs waste systematically grows. Unfortunately androgen-deprivation therapy has numerous side effects such as: the inferior quality of life, sexual disturbances, the fatigue, the anaemia, the bone mineral density loss and the increase of the risk of breaks the bone, the increase of body mass, insulin resistance, hypercholesterolemia, the increased risk of cardiac disorders. The aim of this article is the introduction of the reader with possibly complications androgen-deprivation therapy and with possibilities in diagnosis and treatment.

**Key words:** prostate cancer, androgen deprivation therapy, side effects.

### The side effects of hormonal therapy at the patients with prostate cancer

Ewa Ziółkowska¹, Małgorzata Zarzycka¹, Tomasz Wiśniewski¹,², Agnieszka Żyromska³

¹Department of Radiotherapy I, Oncology Centre – prof. Franciszek Łukaszczyk Memorial Hospital, Bydgoszcz, Poland
²Chair and Clinic of Oncology and Brachytherapy, L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland
³Department of Teleradiotherapy, Oncology Centre – prof. Franciszek Łukaszczyk Memorial Hospital, Bydgoszcz, Poland

### Introduction

Prostate gland cancer is the second most frequent malignant tumor in Poland among men and the third most frequent cause of malignancy-related death [1]. It is established that one in two men suffering from prostate tumor will require hormone therapy at some stage of tumor treatment [2].

Hormonal therapy retards progression of the disease, prevents serious complications and alleviates symptoms of prostate cancer. The aim of the treatment is to reduce the access of prostate cancer cells to testosterone. This is achieved in several ways. First, bilateral orchidectomy leads to the fast decrease of testosterone concentration in the blood. The alternative is pharmacological castration, which is done by cyclical administration of analogs or agonists of luteinizing hormone. In turn, the anti-androgenic drugs block androgen receptors in prostate cancer cells. The combination of pharmacological or surgical castration with anti-androgenic treatment leads to so-called maximum androgen blockade. In long-lasting hormonal therapy a treatment involving periodic gaps in treatment after the patient has reached biochemical regression is recommended (intermittent androgen blockade – IAB). Reactivating the hormonal drugs occurs when successive increase in concentration of prostate-specific antigen (PSA) is observed. This type of treatment can reduce the side effects of the applied therapy and delay the appearance of resistance of prostate cancer to hormonal treatment [3]. Many side effects of hormonal therapy are reported: worse quality of life, sexual dysfunctions, fatigue, anemia, decreased bone density and increased risk of fractures, body mass increase, insulin resistance, hypercholesterolemia, and increased risk of heart diseases [4–8]. These symptoms are independent of the method of hormonal therapy (oral or orchidectomy) and result from reduced concentration of testosterone [4–6].

86% of men suffering from prostate cancer have a disease limited to the prostate gland. In this group five-year survival rates reach up to 100% [9]. Patients suffering from prostate cancer die more often for non-cancer reasons, which is partly connected with the detrimental aftermath of oncological treatment. Due to the good prognosis, in the case of patients with early prostate cancer a treatment should not cause side effects that may affect the quality of life more than the disease itself. Anti-androgen monotherapy is currently rarely used, but must be considered in the case of young people with prostate cancer who want to preserve sexual function. This drug does not reduce testosterone concentration in the blood and hence does not adversely affect erection. On the other hand, anti-androgens can cause diarrhea and a hepatotoxic effect. In the case of maximum androgen blockade, the percentage and inten-
sity of complications (including those involving the stomach, intestine, eyes and hematopoietic system) are larger than in the case of hormonal castration [3]. Intermittent treatment should inherently have a lower risk of complications compared to a continuous hormone therapy. The results of randomized trials aiming to confirm this assumption are expected. The purpose of this article is to present the spectrum of complications of the most commonly used hormonal castration (surgical or medical) and how to effectively prevent and overcome the consequences of this therapy.

**Hot flashes**

Described as a sudden and intense feeling of heat in the face, neck and upper body, which lasts from seconds to an hour. They are considered one of the most common and the most troublesome side effects since they appear in more than 80% of patients with prostate cancer treated with hormonal therapy [10]. Hot flashes are often caused by so-called trigger factors, which include stress, heat, a sudden change in body position, stimulants (coffee, cigarettes, alcohol) and consumption of spicy food [11, 12]. As non-pharmacological measures it is advised to avoid the aforementioned generative triggers, wear clothes made of natural fibers such as linen or cotton, use cold compresses to the neck or drink a glass of cold drink at the onset of symptoms and take regular exercise [11]. If burdensome symptoms keep occurring even after the change of lifestyle according to the recommendations mentioned above, it is advisable to include hormonal drugs: megestrol, cyproterone, nadoxyprogesterone or diethylstilbestrol in low doses. One should remember that these preparations may increase the risk of cardiovascular and thrombotic complications [12, 13]. Of interest to researchers were also new antidepressants, especially citalopram and venlafaxine, but their effectiveness is lower than that of hormonal drugs. Studies to assess the effect of other neuropsychiatric drugs such as gabapentin or clonidine are ongoing [11].

**Feeling of tiredness**

It is classified as one of the most common as well as the most difficult to treat side effects of hormonal therapy. Its escalation may be caused by any other complications of hormonal therapy, e.g. anemia or sarcopenia (skeletal muscles mass loss). The best results of tiredness treatment are achieved by changing one’s lifestyle and introducing specially designed physical exercises. Recommended non-pharmacological methods include not smoking, avoiding stress or great effort, replacing useless work that may waste the patient’s energy with useful work that brings them satisfaction (it stimulates the self-reward mechanism), and avoiding longer than one hour rest in the day time [11]. It is important to balance the time of rest and of activity by resting before the tiredness comes as short breaks are better than a long rest time. It may be helpful to schedule the most important activities during a whole day. Healthy eating and regular physical exercises that prevent the loss of skeletal muscle mass are also crucial [14].

**Sexual dysfunctions**

According to American authors, the most frequently reported side effects of hormonal therapy are lack of interest in sexual intercourse and impotence. In Poland, this problem seems not to have been assessed in depth, probably because it is considered a taboo by both patients and doctors. It is therefore very important for doctors to gain patients’ trust in order to be able to talk about the aspects that are commonly found embarrassing. What is also important is that the problem affects the patient’s wife as well as himself as it requires understanding and cooperation from both of them. It should be explained to the partners that men’s lower level of testosterone does not eliminate his sexuality but changes it. The substitution for sexual life may be found in simple gestures such as holding hands, cuddling or caring about the other person in a special way [11]. When it is necessary to introduce pharmacological treatment, the choice is between prostaglandin injections into the cavernous body of the phallus, which is more effective in maintaining the erection, and drugs containing 5-phosphodiesterase inhibitors, which work well, too, although their effectiveness may be decreased when used with hormone therapy as they require androgens to work [13].

**Psychological effects**

Usually they are cognitive dysfunctions and concentration and memory deterioration followed by emotional instability and bad mood or even depressive episodes [11, 12]. It should be explained to the patient that these symptoms are temporary and caused by the treatment. Some uncommon serious cases require a psychiatric opinion and specially oriented treatment.

**Bone loss and bone fractures**

Some tests showed decrease of bone mass (bone mass density, BMD) and increased risk of bone fractures in cases of patients with prostate gland cancer who were given hormonal drugs [12, 15, 16]. A retrospective study conducted in a group of 50 000 patients proved that 18.4% of patients with prostate gland cancer who underwent hormonal therapy experienced bone fractures while in the group of patients who did not undergo hormonal therapy only 12.6% experienced bone fractures. The risk of fractures was determined by the treatment intensity and was higher in the case of long-term treatment. Also orchidectomy may cause the risk, which means it is connected with reduction of androgen concentrations in the patient’s body and is not determined by the drug’s ingredients [17]. Similar results were obtained in a population study which showed that the use of anti-androgenic drugs may increase the risk of bone fractures (HR 1.65; 95% CI: 1.53–1.77), and the longer the treatment lasts the higher the risk is [5]. In the Wilcox et al. study performed on a group of 174 patients with prostate cancer treated with hormonal therapy (median duration of treatment was 21 months), 24 patients (14%) experienced bone fractures. Among them 11 had 1 bone fracture risk factor and 8 had 2 or more other factors (Table 1).

The most frequent was fracture of the spine [18]. The percentage of fractures was similar as in other studies, where it was 6% to 20% and depended on the observation period.
In a group of healthy men of similar age to the patients, the percentage of bone fractures was 1–2% per year [19]. Another study conducted on a group of 288 people treated with hormonal therapy showed the percentage of bone fractures as 2.7% per year, which was 3 times higher than in a control group of 300 people (0.7% per year) [22]. It was also proven that in men with prostate cancer who experience bone fractures overall survival is also lower (121 months compared to 160 months in a group with no bone fractures) [23]. Decrease of bone density in healthy men aged 65–80 is 0–0.6% per year [6] while after introducing hormonal therapy it grows to 2–5% per year [7, 19, 20] and is noticeable as soon as 6 months after the treatment begins [24].

The first method of preventing osteoporosis is non-pharmacological treatment defined by a change of one’s lifestyle by giving up smoking and limiting alcohol and coffee. Regular physical exercise is recommended as well as a diet rich in calcium and vitamin D [11]. It was proven that giving up smoking and alcohol is enough to reduce the risk of bone density decrease and bone fracture and regular daily physical exercise (20–45-minute sessions 2–4 times a week) may lead in calcium and vitamin D [11]. It was proven that giving up smoking and alcohol is enough to reduce the risk of bone density decrease and bone fracture and regular daily physical exercise (20–45-minute sessions 2–4 times a week) may lead to increase of bone density by 1–2% [25]. Calcium and vitamin D deficiency is frequently diagnosed among patients with prostate cancer [26]. When a patient is diagnosed with osteoporosis (T score < −2.5) it is recommended to include in the treatment vitamin D in the dose of 800–2000 IU/day, and calcium supplementation in the dose of 1200–1500 mg/day because it was proven to lead to a reduction of osteoporosis-caused fractures by 12% [27]. A few authors suggest that all patients with prostate cancer aged over 65 years should be given vitamin D and calcium [11].

### Pharmacological treatment

**Bisphosphonates**

Bisphosphonates should be introduced to the treatment when an osteoporosis-caused fracture occurs or when the T score value drops below 2.5 [11]. They reduce bone resorption by blocking osteoclasts’ activity and they prevent cancer treatment-induced bone loss in the case of patients with prostate globe cancer treated with hormone therapy [25]. However, one should remember about simultaneous calcium and vitamin D supplementation as in the case of lower calcium concentration in the blood the effectiveness of bisphosphonates is decreased [1]. Results of clinical tests evaluating bisphosphonates’ effectiveness in preventing bone loss are presented in Table 2.

### Estrogens

Two studies conducted on a sparse population of patients showed a positive impact of small doses of estrogen (diethylstilbestrol 1 mg/24 h or ethinylestradiol 1 mg/24 h) on concentration of bone resorption markers in patients with prostate cancer treated with hormonal therapy. Unfortunately, the study did not include patients’ bone density or frequency of fracture measurements [34, 35]. A disadvantage of estrogen drugs is that they increase the risk of cardiovascular and thromboembolic complications [25].

### Selective estrogen receptor modulators

These drugs are selectively connected with estrogen receptors in bones. They imitate the positive effect of estrogens on bone metabolism and at the same time they do not cause standard complications of estrogen treatment [25]. One of these drugs is raloxifene. Compared to placebo it causes a significant increase of bone density and decrease of bone resorption markers among patients with prostate cancer treated with anti-androgens [36].

---

**Table 1. Risk factors of bone fractures**

| Risk factor                             |
|----------------------------------------|
| bone fractures in medical history       |
| osteoporosis in the family              |
| low BMI                                 |
| smoking                                 |
| excessive alcohol consumption           |
| steroid therapy                         |
| low level of vitamin D                  |
| duration of hormonal therapy > 6 months|

**Table 2. Review of studies concerning the efficacy of bisphosphonates in prevention of hormonal therapy induced bone loss**

| Author                | Number of patients | Treatment type                          | Average % of BMD changes after treatment |
|-----------------------|--------------------|-----------------------------------------|-----------------------------------------|
|                       | tested group | control group | lumbar spine | hip                        |
| Smith (2001) [28]     | 21           | 22           | pamidronate 60 mg i.v. every 12 weeks (4 injections) vs. control group | 0.0 vs. −3.3 | 0.0 vs. −1.8 |
| Smith (2003) [29]     | 42           | 37           | zoledronic acid 4 mg i.v. every 3 months (4 injections) vs. placebo | 5.6 vs. −2.2 | 1.1 vs. −2.8 |
| Ryan (2006) [30]      | 50           | 51           | zoledronic acid 4 mg i.v. every 3 months (4 injections) vs. placebo | 4.6 vs. −2.1 | 1.4 vs. −2.4 |
| Greenspan (2007) [31] | 56           | 56           | alendronate 70 mg/week, orally for 1 year vs. placebo | 3.7 vs. −1.4 | 0.7 vs. −0.7 |
| Israeli (2007) [32]   | 106          | 109          | zoledronic acid 4 mg i.v. every 3 months (4 injections) vs. placebo | 4.7 vs. −2 | 1.6 vs. −2.1 |
| Michaelson (2007) [33] | 22           | 22           | zoledronic acid 4 mg i.v. one dose/year vs. placebo | 4 vs. −3.1 | 0.7 vs. −1.9 |
New medicines

Denosumab is an interesting drug that is an inhibitor of RANK-L receptor which strongly blocks the action of osteoclasts. Effectiveness of denosumab was proven in various prostate cancer stages: in early stages of the disease it prevents cancer treatment-induced bone loss (CTIBL) and in advanced stages it prevents cancer metastases to bones and bone complications of cancer. In a randomized study including a control group conducted on 1468 patients with prostate cancer with no metastases treated with hormone therapy, patients were given denosumab in a dose of 60 mg/d for 6 months. It was proven that denosumab significantly increased bone density (during a 2-year period: hip by 4.8%, femoral neck by 3.9%, lumbar spine by 6.7%, p < 0.001) and reduced the number of spine fractures by 62% in a 36-month observation period compared to a placebo group [37].

Another randomized study compared the effectiveness of denosumab and zoledronic acid in preventing bone complications. The study included 1901 men with hormone-resistant prostate cancer and metastases to bones. Median patient age was 71 years. The endpoint of the study was skeletal-related events (SRE) defined by occurrence of: pathological fracture, metastases to bones requiring radiotherapy or surgery, or symptoms of spinal cord pressure. In patients treated with denosumab the symptoms occurred later than in patients treated with zoledronic acid (20.7 months vs. 17.1 months, p = 0.008). Overall survival was similar in both groups [38].

Monitoring

According to WHO recommendations, in the case of introducing hormonal therapy to a patient with prostate cancer, regular tests should be performed to estimate bone density and the first test should be performed before therapy starts, while the next ones should take place on a regular basis (Table 3) [39]. A study retrospectively assessing the number of bone fractures after introducing hormonal therapy proved that only 13% of patients had densitometric tests performed and, what is interesting, over 50% of them had bone density lower than the level that meets the criteria of osteoporosis diagnosis [18].

Most authors suggest that each patient starting hormonal therapy should have their bone density checked and bone fracture risk factors defined in order to be classified in a particular risk group, which may steer further management [11, 25]. The risk of bone fractures in patients starting hormonal therapy is defined as high if one or more of the factors mentioned in Table 1 occurs.

| Output value T-score | High risk of fracture | Low risk of fracture |
|----------------------|-----------------------|----------------------|
| norm (to –1)         | 12 months             | 24 months            |
| osteopenia (–1 to –2.5) | 6 months             | 12 months            |
| osteoporosis (more than –2.5) | 6 months             | 6 months             |

Measurement of bone density is usually performed on pelvic girdle bones or on lumbar vertebra. Two techniques with similar properties are used: DEXA (dual energy X-ray absorptiometry) or QCT (quantitative computed tomography). Despite advantages and disadvantages of the two techniques, it is important that each consecutive bone density measurement is performed with the same technique and on the same skeleton area – only then will the result present reliable differences in bone density. The possibilities of using bone resorption markers in monitoring patients are rarely taken advantage of in everyday clinical practice. However, evaluating these markers is easy to perform and potentially less expensive than bone density tests; hence the area requires further research [25].

Metabolic disorders

In a group of 79 patients it was shown that 12-month hormonal therapy causes a weight increase of 1.8%, an increase in body fat of 11% and a decrease in muscle mass by 3.8% [40].

Male hypogonadism, regardless of etiology, always causes loss of muscle tissue mass and a simultaneous increase in the volume of adipose tissue. The observed changes are already noticeable after 3 months of anti-androgen therapy, increase with duration of treatment and are theoretically reversible after androgen supplementation [40, 41]. Reducing the concentration of testosterone results in the development of so-called sarcopenic obesity characterized by muscle atrophy and increase of body fat mass [11]. Next, it can lead to the development of metabolic syndrome characterized by abdominal obesity, hypertension, hyperglycemia, and dyslipidemia [42]. It was shown that the metabolic syndrome increases the risk of death from cardiac infarction, even in the absence of overt coronary artery disease [43]. Also having an effect on the development of obesity is a reduction of physical activity among patients with active anti-androgen treatment, which increases atrophy of muscle tissue. Skeletal muscles work as a regulator of blood glucose level and reduction of their weight causes a sharp increase in peripheral insulin resistance and accelerates the development of type 2 diabetes [11]. Some researchers believe that insulin resistance may be responsible for increased levels of adipokynes (resistin, interleukin 6, tumor necrosis factor α) released from adipose tissue [40]. Hormonal therapy also leads to increased levels of total cholesterol, LDL and triglycerides. On the other hand, it often leads to an increase in HDL, so the impact of these changes on cardiovascular risk is unclear [40].

Cardiovascular complications

A Canadian study evaluating the long-term side effects of anti-androgen therapy was performed for more than 19 thousand patients with prostate cancer who were treated with hormonal therapy for at least 6 months [5]. The control group was selected for age, type of cancer treatment, comorbidities, medication use and risk factors for ischemic heart disease.

The average period of observation was 6.47 years. The endpoints adopted were prevalence of cardiac infarction, sudden cardiac death, diabetes or bone fractures. It was found that hormonal therapy significantly increases the risk of dia-
The side effects of hormonal therapy at the patients with prostate cancer

**Anemia**

Hormonal therapy reduces the concentration of hemoglobin in an indirect mechanism by 10% by reducing the concentration of testosterone, as it has been shown that androgens physiologically enhance erythropoiesis by increasing the production of erythropoietin and directly activate erythrocyte progenitor cells [17, 47].

**Summary**

Hormonal therapy for prostate cancer has increasing indications which should oblige doctors to familiarize themselves with the range of possible complications of the treatment.

This article describes the most common side effects of hormonal treatment and shows the possibility of accurate diagnosis in order to prevent and combat the adverse consequences of this therapy. The basic scope of research in the period of cancer patients’ observation while using hormonal drugs should be expanded to routine measurement of blood pressure, body weight, abdomen circumference, cholesterol, triglycerides and glucose level. However, bone densitometry should be repeated 1–2 years after the beginning of hormonal therapy.

The authors declare no conflict of interest.

**References**

1. Krajowy Rejestr Nowotworów. Available at: http://85.128.14.124/krn.
2. Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology 2002; 60: 7-11.
3. Borowka A, Dobruch J, Chłosta P. Leczenie hormonalne chorych na raka gruczołu krokowego. Przegl Urol 2011; 12: 23-32.
4. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294: 238-44.
5. Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Chung AM, Paszat LF. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009; 27: 3452-8.
6. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90: 6410-7.
7. Shahinian VB, Kuo VF, Freeman JL, Goodwin JS. Risk of the “andro-
gen deprivation syndrome” in men receiving androgen deprivation for prostate cancer. Arch Intern Med 2006; 166: 465-71.

8. Sandra MG, Dunn RL, Michalski J, et al. Quality of life and satisfac-
tion with outcome among prostate-cancer survivors. N Engl J Med 2008; 358: 1255-61.

9. Keating NL. O’Malley AL, Smith MR. Diabetes and cardiovascular dis-
ease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-56.

10. Schow DA, Renfer LG, Rozanski TA, Thompson IM. Prevalence of hot
flashes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J 1998; 91: 855-7.

11. Tombal B. A holistic approach to androgen deprivation therapy: treat-
ing the cancer without hurting the patient. Urol Int 2009; 83: 20-7.

12. Holzbeierlein JM. Managing complications of androgen deprivation
therapy for prostate cancer. Urol Clin North Am 2006; 33: 181-90.

13. Mottet N. Prayer-Galetti T, Hammerer P, Kattan MW, Tunn L. Opti-
mizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int 2006; 98: 20-7.

14. Knols R, Aaronson NK, Lebelhant D, Fransen J, Aufdemkampe G. Phys-

15. Shahinian VB, Kuo VF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-64.

16. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-
based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 7897-903.

17. Shahidi NT. Androgens and erythropoiesis. N Engl J Med 1973; 289: 72-80.

18. Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, Elliott ME. Androgen deprivation in veterans with prostate cancer: implications for skeletal health. Ann Pharmacother 2006; 40: 2107-14.

19. Shahinian VB, Kuo VF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-64.

20. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-
based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 7897-903.

21. Maxwell C. Vialle PH. Cancer treatment-induced bone loss in patients with breast or prostate cancer. Oncol Nurs Forum 2005; 32: 589-603.

22. López AM, Pena MA, Hernández R, Val F, Martin B, Riancho JA. Frac-
ture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int 2005; 16: 707-11.

23. Oefelein MG, Ricchuti V, Conrad W, Seftel A, Bodner D, Goldman H, Resnick M. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001; 166: 1724-8.

24. Hatano T, Oishi Y, Furuta A, Iwamura S, Tashiro K. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 2000; 86: 2125-30.

25. D’Amico AV, Denham JW, Crook J, et al. Influence of androgen sup-
pression therapy for prostate cancer on the electrocardiographic QT inter-
val. J Clin Oncol 2004; 22 (14S): 4578.

26. Saigal CS, Gore JL, Kronski TL, Hanley J, Schonlau M, Litwin MS; And

27. Hofer N. Randomized controlled trial of zoledronic acid to prevent bone
loss in men receiving androgen deprivation therapy for non-
metastatic prostate cancer. J Urol 2003; 169: 2007-12.

28. Shahani S, Androgen deprivation for prostate cancer. BJU Int 2006; 98: 20-7.

29. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, KANTOP PW, Finkelstein JS. Pamide in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. J Urol 2002; 168: 1005-7.

30. Ryan CW, Huo D, Demers LM, Beer TM, Lascena L. Zoledronic acid ini-
tiated during the first year of androgen deprivation therapy increas-
es bone mineral density in patients with prostate cancer. J Urol 2006; 175: 972-8.

31. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-week-
ly oral alendronate on bone loss in men receiving androgen depriva-
tion therapy for prostate cancer: a randomized trial. Ann Intern Med 2007; 146: 416-24.

32. Israeli RS, Rosenberg SJ, Saltzstein DR, et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen depriva-
tion therapy. Clin Genitourin Cancer 2007; 5: 271-7.

33. Michaelson MD, Kaufman DS, Lee H, McGovern FJ, KANTOP PW, Fal-
lon MA, Finkelstein JS, Smith MR. Randomized controlled trial of annu-
al zoledronic acid to prevent gonadotropin-releasing hormone ago-
nist–induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25: 3083-92.

34. Scherr D, Pitts WR Jr, Vaughn ED Jr. Diethylstilbestrol revisited: andro-
gen deprivation, osteoporosis and prostate cancer. J Urol 2002; 167: 535-8.

35. Taxel P, Fall PM, Albertsen PC, Dowsett RD, Tatriots M, Zimmerman J, O’hannessian C, Raiss LG. The effect of micronized estradi-
ol on bone turnover and calcitropic hormones in older men receiv-
ing hormonal suppression therapy for prostate cancer. J Clin Endocrinol Metab 2002; 7: 4907-13.

36. Smith MR, Fallon MA, Lee H, Finkelstein JS. Roloxifene to prevent
gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004; 89: 3601-6.

37. Smith MR, Egerdie B, Hernández Toriz N, et al.; Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving andro-
gen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745-55.

38. Fizzi K, Carducci M, Smith M, et al. Denosumab versus zoledron-
ic acid for treatment of bone metastases in men with castration-
resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 9768: 813-22.

39. Diamond TH, Higano CS, Smith MR, Guse TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004; 100: 892-9.

40. Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 2008; 93: 2042-9.

41. Basaria S, Wahlsrom JT, Dobs AS. Anabolic-androgenic steroid ther-
apy in the treatment of chronic diseases. J Clin Endocrinol Metab 2001; 86: 5108-13.

42. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24: 3979-83.

43. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and car-
diovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-16.

44. D’Amico AV, Denham JW, Crook J, et al. Influence of androgen sup-
pression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007; 25: 2420-5.

45. Saigal CS, Gorn JL, Kruipski TL, Hanley J, Schonlau M, Litwin MS; And

46. Garnick MB, Pratt CM, Campion M, Shipley J. The effect of hormonal ther-
apy for prostate cancer on the electrocardiographic QT inter-
val: Phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelax. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004; 22 (14S): 4578.

47. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004; 63: 742-5.
Address for correspondence

Ewa Ziółkowska
Department of Radiotherapy I
Oncology Centre – prof. Franciszek Łukaszczyk Memorial Hospital
I. Romanowskiej 2
85-796 Bydgoszcz
e-mail: ziolkowskae@co.bydgoszcz.pl

Submitted: 19.06.2011
Accepted: 7.08.2012